(AOF) – Sanofi indicated that the American Food and Drug Administration (FDA) had granted priority review to the drug Sarclisa. If approved, it could be the first anti-CD38, in combination with standard-of-care chemotherapy, for patients with newly diagnosed multiple myeloma who are not eligible for transplantation. This would be the third indication for Sarclisa for the treatment of multiple myeloma. The FDA is expected to make its decision on September 27, 2024. A regulatory submission is also under consideration in the European Union.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
